NCT03531229View on ClinicalTrials.gov

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

February 22, 2019

Study Completion Date

February 22, 2019

Conditions
Healthy
Interventions
DRUG

Placebo

Placebo to Lu AF76432 oral solution

DRUG

Lu AF76432

Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

Trial Locations (1)

Unknown

Parexel Early Phase Clinical Unit, Harrow

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03531229 - Single Ascending Dose Study of Lu AF76432 in Healthy Young Men | Biotech Hunter | Biotech Hunter